TL;DR
This study investigated whether GLP-1 receptor agonists (GLP1-RAs), commonly used for type 2 diabetes, impact diabetic retinopathy (DR) progression, vision, or the effectiveness of eye injections. While preliminary findings suggest no significant difference in DR progression or vision changes, GLP1-RAs might be associated with a better response to intravitreal injections, though this effect is confounded by pre-existing eye conditions.
What Problem Does This Paper Address?
Diabetic retinopathy (DR) is a major cause of vision loss in people with diabetes. Current treatments include intravitreal injections (IVIs) of anti-VEGF medications. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are a class of drugs that improve blood sugar control and have shown some potential for protecting the eyes. However, the existing research on GLP1-RAs' effects on DR progression and ocular health is mixed and often lacks detailed ophthalmological data. This paper aims to clarify the relationship between GLP1-RA use and DR outcomes, specifically looking at DR progression, visual acuity (VA), central subfield thickness (CST) measured by OCT, and how well patients respond to IVIs.
Methods
This was a retrospective, medical record-based study. The researchers identified patients with DR from the Hadassah ophthalmological cohort. They compared a group of 35 patients who were new to GLP1-RA treatment (GLP1-RA group) with a control group of 31 patients with DR who did not receive GLP1-RAs. Both groups had at least one year of follow-up and ophthalmological data, including optical coherence tomography (OCT) scans. Key outcomes measured included DR progression (defined by changes in DR severity scale), changes in visual acuity (logMAR), changes in central subfield thickness (CST), and the response to intravitreal injections (categorized as "Good," "Stable," or "Poor"). Statistical analyses included t-tests, chi-square tests, and logistic regression to compare groups and identify associations.
Datasets
The study utilized data from the Hadassah ophthalmological cohort, comprising medical records and OCT images of 4500 patients with DR. From this, 146 patients were identified as having started a GLP1-RA treatment. The final analysis included 35 GLP1-RA-naïve patients and 31 control patients who met specific inclusion criteria, including at least one year of follow-up and specific OCT/fundus examination timing. No new datasets were introduced.
Key Insights and Ideas
- GLP1-RAs and DR Progression: While the GLP1-RA group showed a slightly higher rate of DR progression, this difference was not statistically significant, suggesting GLP1-RAs may not dramatically worsen or improve DR progression in this cohort.
- Visual Acuity and CST Stability: The study found no significant differences in the change of visual acuity or central subfield thickness between patients on GLP1-RAs and the control group. This indicates that, within the study's timeframe, GLP1-RAs did not appear to significantly impact these key vision-related metrics.
- IVI Response Nuances: There was a trend towards a better response to intravitreal injections (IVIs) in the GLP1-RA group. However, this association was confounded by the presence of vitreous hemorrhage and hyperreflective retinal foci (HRF), suggesting these pre-existing ocular conditions play a significant role in IVI response, potentially masking or altering the perceived effect of GLP1-RAs.
- Confounding Factors are Crucial: The study strongly emphasizes the importance of considering ocular parameters like vitreous hemorrhage and HRF when evaluating the impact of systemic medications like GLP1-RAs on eye health and treatment response.
Key Results
- DR Progression: 15.8% (3/19) of the GLP1-RA group showed DR progression compared to 0% (0/20) in the control group (p=0.106).
- IVI Response: The GLP1-RA group showed a trend towards better IVI response (27/35 vs. 17/31, unadjusted OR: 2.78, p=0.058). However, after adjusting for vitreous hemorrhage and HRF, this association was no longer significant (adjusted OR: 1.76, p=0.229).
- Visual Acuity Change: No significant difference was observed (-0.135 logMAR for GLP1-RA vs. -0.063 logMAR for control, p=0.664).
- CST Change: No significant difference was observed (-13.49 µm for GLP1-RA vs. -30.13 µm for control, p=0.464).
- Baseline Differences: The GLP1-RA group had a higher prevalence of vitreous hemorrhage (45.7% vs. 19.4%, p=0.023) and hyperreflective retinal foci (HRF) (35.5% vs. 11.4%, p=0.02) at baseline.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: This limits the ability to establish causality and relies on existing medical records.
- Small Sample Size: With only 66 patients in total, the study has limited statistical power to detect subtle differences or trends.
- Short Follow-up Duration: A one-year follow-up is relatively short for assessing long-term DR progression.
- Limited GLP1-RA Analogs: The study primarily included liraglutide and semaglutide, so findings may not generalize to all GLP1-RAs.
- Potential Information and Selection Bias: Inaccuracies in records or the selection of patients with more severe DR or comorbidities could influence results.
Future work should involve larger, prospective studies with longer follow-up periods and a broader range of GLP1-RA analogs to provide more robust insights into their ocular effects. Further investigation into the role of specific ocular parameters like HRF and vitreous hemorrhage as confounders is also warranted.
Summary updated